Humira, Rituxan top list of U.S. drugs with biggest price increases: report
AbbVie Inc's rheumatoid arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. (Source: Reuters: Health)
Source: Reuters: Health - October 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Rituxan Approved for Pediatric Patients With Rare Vasculitis Diseases
Title: Rituxan Approved for Pediatric Patients With Rare Vasculitis DiseasesCategory: Health NewsCreated: 10/1/2019 12:00:00 AMLast Editorial Review: 10/2/2019 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - October 2, 2019 Category: Rheumatology Source Type: news

Rituxan Approved for Pediatric Patients With Rare Vasculitis Diseases
TUESDAY, Oct. 1, 2019 -- Rituxan (rituximab) injection was granted the first approval for a drug to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in combination with glucocorticoids in children 2 years and older,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 1, 2019 Category: General Medicine Source Type: news

FDA OKs First Treatment for Rare Types of Vasculitis in Kids FDA OKs First Treatment for Rare Types of Vasculitis in Kids
The FDA has approved rituximab injection for granulomatosis with polyangiitis and microscopic polyangiitis in children aged 2 years or older.FDA Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 30, 2019 Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news

FDA approves Roche ’s Rituxan (rituximab) in children with two rare blood vessel disorders
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan ® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in paediatric patients 2 years of age and older. (Source: Roche Media News)
Source: Roche Media News - September 30, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Rituxan (rituximab) in children with two rare blood vessel disorders
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan ® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in paediatric patients 2 years of age and older. (Source: Roche Investor Update)
Source: Roche Investor Update - September 30, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Rituxan (rituximab) for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in Children
South San Francisco, CA -- September 27, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab), in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 27, 2019 Category: Drugs & Pharmacology Source Type: news

Abatacept, Rituximab, Tocilizumab and TNFi Biologics in RA Abatacept, Rituximab, Tocilizumab and TNFi Biologics in RA
How do these drugs for the treatment of rheumatoid arthritis compare in terms of efficacy and outcomes?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Can m7 FLIPI Score Predict Prognosis in Follicular Lymphoma?
A new study evaluated whether  the m7-FLIPI score in patients with follicular lymphoma treated with rituximab without chemotherapy can indicate prognosis. (Source: CancerNetwork)
Source: CancerNetwork - September 13, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Genentech nears trade secrets suit settlement with Taiwanese company but still targeting former employees
Biotech powerhouse Genentech Inc. is close to settling a with a Taiwanese company that allegedly stole trade secrets and planned to launch a look-alike version of one of Genentech's most popular drugs. The settlement between the South San Francisco-based U.S. unit of drug giant Roche and JHL Biotech Inc. requires the Taiwanese company to stop development of biosimilar versions of Genentech's cancer drugs Rituxan, Herceptin and Avastin — all multibillion-dollar biologics — and the cystic fibr osis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 7, 2019 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Genentech nears trade secrets suit settlement with Taiwanese company but still targeting former employees
Biotech powerhouse Genentech Inc. is close to settling a with a Taiwanese company that allegedly stole trade secrets and planned to launch a look-alike version of one of Genentech's most popular drugs. The settlement between the South San Francisco-based U.S. unit of drug giant Roche and JHL Biotech Inc. requires the Taiwanese company to stop development of biosimilar versions of Genentech's cancer drugs Rituxan, Herceptin and Avastin — all multibillion-dollar biologics — and the cystic fibr osis… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 7, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news

Ibrutinib Combo in Chronic Lymphocytic Leukemia is Superior, but Costly
While  ibrutinib plus rituximab may improve progression-free survival in chronic lymphocytic leukemia, it is a costly option for some patients. (Source: CancerNetwork)
Source: CancerNetwork - September 3, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Amgen and Allergan announce positive top-line results from comparative clinical study of ABP 798, biosimilar candidate to Rituxan ® (rituximab)
Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan® (rituximab), compared to Rituxan in patients with CD20-positive B-cell non-Hodgkin's lymphoma. (Source: World Pharma News)
Source: World Pharma News - August 22, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Nanocapsule reaches cancer that has spread to central nervous system in mice
FINDINGSCancer that has spread to the central nervous system is notoriously difficult to treat. Now, UCLA researchers have developed a drug delivery system that breaks through the blood-brain barrier in order to reach and treat cancer that has spread to the central nervous system.In research conducted in mice, a single dose of cancer drugs in a nanoscale capsule developed by the scientists eliminated all B-cell lymphoma that had metastasized to the animals ’ central nervous system.BACKGROUNDAbout 15% to 40% of all cancers spread to the nervous system, but there are few treatment options and they only work in a small numb...
Source: UCLA Newsroom: Health Sciences - August 14, 2019 Category: Universities & Medical Training Source Type: news

Examining MRD-Driven Consolidation with Rituximab in Early Stage Follicular Lymphoma
Patients with follicular lymphoma who were minimal residual disease-positive after undergoing involved field radiation therapy were given  rituximab to see how it affected progression-free survival.  (Source: CancerNetwork)
Source: CancerNetwork - August 12, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news